Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6529978rdf:typepubmed:Citationlld:pubmed
pubmed-article:6529978lifeskim:mentionsumls-concept:C0000477lld:lifeskim
pubmed-article:6529978lifeskim:mentionsumls-concept:C0441472lld:lifeskim
pubmed-article:6529978lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:6529978lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:6529978lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:6529978pubmed:issue2lld:pubmed
pubmed-article:6529978pubmed:dateCreated1985-4-26lld:pubmed
pubmed-article:6529978pubmed:abstractTextThe pharmacological actions of 2,4-diaminopyridine (2,4-DAP) and 3-[(dimethylamino)-carbonyl] amino 4-aminopyridine (LF-14) were examined and compared with those of 4-aminopyridine (4-AP) in anaesthetized rats and on isolated rat and guinea-pig tissues. Both compounds were more potent than 4-AP in reversing the neuromuscular block caused by pancuronium bromide. The ED50S of LF-14, 2,4-DAP and 4-AP were 100 micrograms/kg, 140 micrograms/kg and 450 micrograms/kg, respectively. LF-14 and 2,4-DAP were also more potent in their in vitro actions on the neuroeffector junctions in the ileum and the isolated heart. 2,4-DAP and LF-14 either did not facilitate or only slightly facilitated the recovery time from xylazine/ketamine anaesthesia which was used as a test for their central action; 4-AP significantly reduced the recovery time. We therefore conclude that both 2,4-DAP and LF-14 are stronger peripherally acting compounds with less central action, and that they may be possible replacements for 4-AP as antagonists of non-depolarizing muscle relaxants.lld:pubmed
pubmed-article:6529978pubmed:languageenglld:pubmed
pubmed-article:6529978pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6529978pubmed:citationSubsetIMlld:pubmed
pubmed-article:6529978pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6529978pubmed:statusMEDLINElld:pubmed
pubmed-article:6529978pubmed:monthNovlld:pubmed
pubmed-article:6529978pubmed:issn0014-2999lld:pubmed
pubmed-article:6529978pubmed:authorpubmed-author:HornA SASlld:pubmed
pubmed-article:6529978pubmed:authorpubmed-author:AgostonSSlld:pubmed
pubmed-article:6529978pubmed:authorpubmed-author:BiesselsP TPTlld:pubmed
pubmed-article:6529978pubmed:issnTypePrintlld:pubmed
pubmed-article:6529978pubmed:day13lld:pubmed
pubmed-article:6529978pubmed:volume106lld:pubmed
pubmed-article:6529978pubmed:ownerNLMlld:pubmed
pubmed-article:6529978pubmed:authorsCompleteYlld:pubmed
pubmed-article:6529978pubmed:pagination319-25lld:pubmed
pubmed-article:6529978pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:meshHeadingpubmed-meshheading:6529978-...lld:pubmed
pubmed-article:6529978pubmed:year1984lld:pubmed
pubmed-article:6529978pubmed:articleTitleComparison of the pharmacological actions of some new 4-aminopyridine derivatives.lld:pubmed
pubmed-article:6529978pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6529978pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:6529978pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6529978lld:pubmed